-
Featured
Gene Profiling of Bladder Tumors Shows Promise for Identifying Candidates for Trimodality Therapy
Research by Massachusetts General Hospital Cancer Center oncologists suggests gene profiling of tumors from patients with muscle-invasive bladder cancer can guide rational selection of those who will benefit most from bladder-preserving trimodality therapy.
-
Auto-Contouring Model Performs Well for Prostate Cancer Patients Who Receive Radiopaque Hydrogel Spacer
Yi Wang, PhD, Jason A. Efstathiou, MD, DPhil, and colleagues have validated a CT-based deep learning model that provides automated contouring when planning radiation therapy for prostate cancer patients who receive the SpaceOAR Vue rectal spacer.
-
Radiation Oncology Department Announces First-Ever Director of DE&I: Q&A with Sophia Kamran, MD
Sophia Kamran, MD, first-ever Diversity, Equity, and Inclusion (DE&I) director for Mass General Cancer Center's Radiation Oncology department, shares more about her work in this space.
-
High MRE11 in Muscle-invasive Bladder Tumors Linked to Better Survival After Chemoradiation
Using a digital immunofluorescence assay, Jason A. Efstathiou, MD, DPhil, and colleagues showed the DNA repair protein MRE11 could guide the selection of candidates for bladder-sparing trimodality therapy for muscle-invasive bladder cancer, as higher levels were associated with 58% better cumulative four-year survival.
-
Editorial: Dispelling Myths That May Deter Women From Pursuing Radiology and Radiation Oncology
Misconceptions about the fields of radiology and radiation oncology may deter women from pursuing these specialties. Shadi A. Esfahani, MD, and colleagues explain both fields are highly collaborative and interpersonal, offer ample opportunity for work–life integration, and provide a high level of career satisfaction.
-
COVID-19 Severely Interfered With Cancer Imaging in 2020
Marc D. Succi, MD, Ottavia Zattra, and colleagues warn oncologists to plan for a surge of new and more advanced cancer diagnoses in upcoming months and years because of suboptimal CT imaging during—and after—the peak of the COVID-19 pandemic.
Mass General Cancer Center Contributors
-
David T. Miyamoto, MD, PhD
Attending Radiation Oncologist, Department of Radiation Oncology, Massachusetts General Hospital, Investigator, Center for Cancer Research, Mass General Cancer Center, Assistant Professor of Radiation Oncology, Harvard Medical School
Recent Article
High MRE11 in Muscle-invasive Bladder Tumors Linked to Better Survival After Chemoradiation -
Jason A. Efstathiou, MD, DPhil
Vice-Chair, Faculty & Academic Affairs, Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic, Massachusetts General Hospital
Recent Article
Auto-Contouring Model Performs Well for Prostate Cancer Patients Who Receive Radiopaque Hydrogel Spacer -
Theodore Sunki Hong, MD
Director, Gastrointestinal Service, Department of Radiation Oncology, Associate Clinical Director, Department of Radiation Oncology
-
William Shipley, MD
Andres Soriano Distinguished Professor of Radiation Oncology, Harvard Medical School
Recent Article
Alternative Chemoradiation Regimen of Trimodal Therapy Found Effective for Muscle-invasive Bladder Cancer
Mass General Department of Radiation Oncology
The Department of Radiation Oncology combines clinical expertise, compassionate care, and advanced radiation therapies to deliver the safest, most effective treatments for cancer and benign tumors.
